Cancer Rx, LLC recently secured a major technological breakthrough with the issuance of U.S. Patent No. 12773580. This patent, titled ‘Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery’, introduces a powerful way to monitor and treat localized tumors. Invented by Gholam A. Peyman, Michael Kolios, Celina Yang, Jahangir Tavakkoli, Elyas Shaswary, Hisham Assi, and Joseph Carl Kumaradas, the method utilizes photoacoustic imaging and radio-frequency data to accurately determine the temperature of heated tissues and nanocarriers at a tumor site.
FEDERAL PATENT OF THE MONTH – NOVEMBER 2026
The innovation focuses on a novel approach to ultrasound thermometry and targeted drug delivery. By measuring the change in backscattered energy of acoustic harmonics, the system overcomes common challenges related to tissue motion, providing a highly sensitive and precise temperature reading. This allows medical practitioners to excite anti-tumor medication within nanocarriers using specific thermal or non-thermal ultrasound modes safely and effectively. Swanson Reed recognized this invention as the Federal Patent of the Month for November 2026 because it demonstrates exceptional technical advancement in cancer treatment and offers a highly accurate, non-invasive method for localizing therapy without damaging surrounding healthy tissue.
Research and Development Tax Credit Applications
The practical applications and development phases of this medical technology are highly relevant for United States Research and Development tax credit eligibility. Creating a precise thermometry system capable of tracking minute temperature changes in active biological tissue requires overcoming significant technical uncertainties. The engineering process involves an iterative cycle of experimentation, including acoustic modeling, ultrasound software development, and the formulation of nanocarriers for targeted medication release. These development activities directly align with the requirements of Internal Revenue Code Section 41. Businesses in the medical device and biotechnology sectors that invest resources into designing such functional improvements can leverage these credits to offset costs and support further industrial innovation.
